| Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction. | |
| | |
MedLine Citation:
|
PMID: 3315574 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Preliminary investigations using a single intracoronary dose of APSAC (up to 30U) revealed dissolution of intracoronary thrombi in 59 of 83 patients (71%) with acute myocardial infarction, as indicated by reperfusion of coronary arteries. Reocclusion of arteries occurred in 20.5% of patients. Based on these findings, a subsequent study was undertaken in 302 patients with evidence of recent acute myocardial infarction. Single intravenous bolus doses of APSAC (5 to 30U) produced reperfusion in 79% of patients, with reocclusion occurring in only 9% of patients receiving the higher doses. Adverse effects included an initial hypotension/bradycardia reaction, a later syndrome featuring pyrexia, nausea and vomiting, and bleeding complications, including 4 patients with cerebrovascular accidents. In these early studies APSAC appeared to be as effective as streptokinase, as reported in the literature, and to produce a lower incidence of reocclusion than tissue plasminogen activator. |
| | |
Authors:
|
D Jackson |
Related Documents
:
|
3757184 - Risk stratification for 1 year survival based on characteristics identified in the earl... 3432204 - Prolonged diuretic administration and myocardial tolerance to ischaemia. 8625544 - Kawasaki syndrome: immunomodulatory benefit and potential toxin neutralization by intra... 10404864 - Effect of intravenous magnesium on heart rate and heart rate variability in patients wi... 9138094 - Vasculogenesis and angiogenesis: extracellular matrix remodeling in coronary collateral... 2423974 - Internal cardiac defibrillation threshold: effects of acute ischemia. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Drugs Volume: 33 Suppl 3 ISSN: 0012-6667 ISO Abbreviation: Drugs Publication Date: 1987 |
Date Detail:
|
Created Date: 1988-01-07 Completed Date: 1988-01-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7600076 Medline TA: Drugs Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 104-11 Citation Subset: IM |
Affiliation:
|
Beecham Pharmaceuticals Research Division, Brockham Park, Betchworth. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anistreplase Clinical Trials as Topic Coronary Angiography Coronary Circulation / drug effects Dose-Response Relationship, Drug Fibrinolytic Agents / adverse effects, therapeutic use* Heart Catheterization Humans Infusions, Intra-Arterial Injections, Intravenous Myocardial Infarction / drug therapy* Plasminogen / adverse effects, therapeutic use* Streptokinase / adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Highly differentiated adenocarcinoma in a villous adenoma of the common bile duct near the papilla
Next Document: Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylat...